首页 › 基金 › Affinity Asset Advisors, LLC › PTGX
Affinity Asset Advisors, LLC 对 PTGX 的持仓历史
PROTAGONIST THERAPEUTICS INC · 医疗保健
Affinity Asset Advisors, LLC 在 Q3 2026 的 13F 申报中披露持有 PTGX(PROTAGONIST THERAPEUTICS INC)172,125 股,市值约 US$24.3M,约占其申报组合的 1.13%,在其申报持仓中市值排名第 27 位。 Affinity Asset Advisors, LLC 最近 11 个申报季度中有 9 个季度披露了 PTGX 持仓,最早可追溯至 Q1 2024。
最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR
Affinity Asset Advisors, LLC 对 PTGX 的持仓演变
Affinity Asset Advisors, LLC 于 Q1 2024 首次披露 PTGX 持仓:100,000 股(约 US$2.9M)。 该持仓在 Q2 2025 达到峰值 440,000 股,市值约 US$24.3M。 在 9 次申报中,Affinity Asset Advisors, LLC 2 次增持、2 次减持、3 次保持不变。 最近一期申报(Q3 2026)显示持股 172,125 股、市值约 US$24.3M。 持仓曾出现大幅变动:Q1 2025 增持约 33% (随后一个季度股价上涨 14%)、Q2 2025 增持约 155% (随后一个季度股价上涨 20%)、Q3 2025 减持约 50% (随后一个季度股价上涨 31%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2024 | 100.00K | $2.89M | 新进 |
| Q4 2024 | 130.00K | $5.02M | 新进 |
| Q1 2025 | 172.50K | $8.34M | 增持 |
| Q2 2025 | 440.00K | $24.32M | 增持 |
| Q3 2025 | 220.60K | $14.65M | 减持 |
| Q4 2025 | 172.12K | $15.03M | 减持 |
| Q1 2026 | 172.12K | $18.14M | 持有 |
| Q2 2026 | 172.12K | $21.10M | 持有 |
| Q3 2026 | 172.12K | $24.25M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 PTGX 与 13F 数据
PTGX(PROTAGONIST THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 50 只申报持有 PTGX,申报仓位最大的包括:法拉龙资本管理 (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 PTGX 的基金
- 法拉龙资本管理 6.35M 股 · $778.25M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.35M 股 · $778.25M · Q2 2026
- RTW INVESTMENTS, LP 5.06M 股 · $620.40M · Q2 2026
- JOHNSON & JOHNSON 2.45M 股 · $345.07M · Q3 2026
- Woodline Partners LP 1.41M 股 · $173.35M · Q2 2026
- PERCEPTIVE ADVISORS LLC 981.88K 股 · $120.36M · Q2 2026
- ADAR1 Capital Management, LLC 960.86K 股 · $117.78M · Q2 2026
- Hood River Capital Management LLC 882.74K 股 · $108.21M · Q2 2026
- 683 Capital Management, LLC 290.00K 股 · $35.55M · Q2 2026
- Eagle Health Investments LP 248.32K 股 · $34.99M · Q3 2026
- NEXTBio Capital Management LP 219.33K 股 · $30.90M · Q3 2026
更多关于 Affinity Asset Advisors, LLC
常见问题
How long has Affinity Asset Advisors, LLC held PTGX?
Affinity Asset Advisors, LLC has disclosed PTGX holdings in 9 of the last 11 reported quarters, going back to Q1 2024.
What is Affinity Asset Advisors, LLC's current position in PTGX?
As of Q3 2026, Affinity Asset Advisors, LLC holds 172.12K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $24.25M, representing 1.13% of its reported portfolio and ranking #27.
Has Affinity Asset Advisors, LLC been buying or selling PTGX?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC held unchanged its position in PTGX. The position peaked in Q2 2025 at 440.00K shares.
Which other funds hold PTGX?
Other major institutional holders of PTGX include 法拉龙资本管理, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.